Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy

• 資料種別: 記事
• タイトル: Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy
• 著者・編者: Waka Ohishi; Kazuaki Chayama
• 出版事項: 日本 : Springer Nature
• 出版年月日等: 2011-06-01
• 出版年（W3CDTF）: 2011-06-01
• タイトル（掲載誌）: Clinical and experimental nephrology : official publication of the Japanese Society of Nephrology
• 巻号年月日等（掲載誌）: 15(5)
• 掲載巻: 15(5)
• ISSN（掲載誌）: 1437-7799
• ISSN-L（掲載誌）: 1437-7799
• 本文の言語コード: eng
• DOI: 10.1007/s10157-011-0464-7; https://doi.org/10.1007/s10157-011-0464-7
• 国立国会図書館永続的識別子: info:ndljp/pid/11553500; https://dl.ndl.go.jp/pid/11553500
• コレクション（共通）: 障害者向け資料
• コレクション（障害者向け資料：レベル1）: テキストデータ
• コレクション（個別）: 国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > その他; https://dl.ndl.go.jp/collections/B00035
• 収集根拠: オンライン資料収集制度
• 受理日（W3CDTF）: 2020-10-08T21:45:28+09:00
• 保存日（W3CDTF）: 2020-06-16
• 記録形式（IMT）: application/pdf
• オンライン閲覧公開範囲: 国立国会図書館内限定公開
• デジタル化資料送信: 図書館・個人送信対象外
• 遠隔複写可否（NDL）: 可
• 掲載誌（URI）: https://link.springer.com/journal/10157/15/5
• 掲載誌（国立国会図書館永続的識別子）: info:ndljp/pid/11553497; https://dl.ndl.go.jp/pid/11553497
• 連携機関・データベース: 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

• 要約等: コレクション : 国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > その他
• DOI: 10.1007/s10157-011-0464-7; https://doi.org/10.1007/s10157-011-0464-7
• 関連情報（URI）: http://id.ndl.go.jp/digimeta/11553500; https://dl.ndl.go.jp/pid/11553500; http://link.springer.com/content/pdf/10.1007/s10157-011-0464-7.pdf; http://link.springer.com/article/10.1007/s10157-011-0464-7/fulltext.html; http://link.springer.com/content/pdf/10.1007/s10157-011-0464-7
• 参照: Cost-effectiveness of managing HBV reactivation in patients with resolved HBV infection treated with anti-CD20 antibody for B-cell non-Hodgkin lymphoma; https://cir.nii.ac.jp/crid/1360016862132723200
• 参照: Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan; https://cir.nii.ac.jp/crid/1050282813895513856; Hepatitis B virus DNA contains a glucocorticoid-responsive element.; https://cir.nii.ac.jp/crid/1360011144011577472; Serial Studies of Hepatitis-Associated Antigen and Antibody in Patients Receiving Antitumor Chemotherapy for Myeloproliferative and Lymphoproliferative Disorders; https://cir.nii.ac.jp/crid/1360011145612288512; Kinetics and Risk of De Novo Hepatitis B Infection in HBsAg–Negative Patients Undergoing Cytotoxic Chemotherapy; https://cir.nii.ac.jp/crid/1360011145818484992; Rituximab for refractory focal segmental glomerulosclerosis; https://cir.nii.ac.jp/crid/1360292619014585088; Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis; https://cir.nii.ac.jp/crid/1360574093895519872; Long-Term Clinical Remission Induced by Corticosteroid Withdrawal Therapy (CSWT) in Patients with Chronic Hepatitis B Infection: A Prospective Randomized Controlled Trial—CSWT with and Without Follow-Up Interferon-α Therapy; https://cir.nii.ac.jp/crid/1360574094342671488; Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy; https://cir.nii.ac.jp/crid/1360574094568536064; Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients; https://cir.nii.ac.jp/crid/1360574094597335808; Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab; https://cir.nii.ac.jp/crid/1360574094632531456; Liver Transplantation in European Patients with the Hepatitis B Surface Antigen; https://cir.nii.ac.jp/crid/1360574095163453568; THE IMPACT OF RENAL TRANSPLANTATION ON THE COURSE OF HEPATITIS B LIVER DISEASE; https://cir.nii.ac.jp/crid/1360574096500182016; Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease; https://cir.nii.ac.jp/crid/1360585448867341696; Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy; https://cir.nii.ac.jp/crid/1360855568629382912; Lamivudine Therapy for Chemotherapy-Induced Reactivation of Hepatitis B Virus Infection; https://cir.nii.ac.jp/crid/1360855570345339008; Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta‐analysis; https://cir.nii.ac.jp/crid/1360863108243854592; Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma; https://cir.nii.ac.jp/crid/1361137044530342784; Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #; https://cir.nii.ac.jp/crid/1361137045436302080; Current treatment for chronic hepatitis B in Japan; https://cir.nii.ac.jp/crid/1361137046328897408; Growth Inhibition of CD20‐positive B Lymphoma Cell Lines by IDEC‐C2B8 Anti‐CD20 Monoclonal Antibody; https://cir.nii.ac.jp/crid/1361137046391340928; Change of hepatitis B virus genotypes in acute and chronic infections in Japan; https://cir.nii.ac.jp/crid/1361418518402845952; Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers; https://cir.nii.ac.jp/crid/1361418519080403712; Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1361418519285161856; Rituximab therapy for steroid-dependent minimal change nephrotic syndrome; https://cir.nii.ac.jp/crid/1361418520929056128; Hepatitis B Virus Infection; https://cir.nii.ac.jp/crid/1361418521133119360; Unexpected Efficacy of Rituximab in Multirelapsing Minimal Change Nephrotic Syndrome in the Adult: First Case Report and Pathophysiological Considerations; https://cir.nii.ac.jp/crid/1361699994766557312; Use of entecavir to prevent hepatitis B virus reactivation during cytotoxic chemotherapy for solid malignancy; https://cir.nii.ac.jp/crid/1361699995603071104; Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies; https://cir.nii.ac.jp/crid/1361699995605002752; Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease; https://cir.nii.ac.jp/crid/1361981468721560192; Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan; https://cir.nii.ac.jp/crid/1361981469184338432; Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: A review of 16 patients; https://cir.nii.ac.jp/crid/1361981469479239808; The infectious profiles of anti‐tumor necrosis factor agents in a Thai population: a retrospective study a the university‐based hospital; https://cir.nii.ac.jp/crid/1361981470190961792; Risk Factors for Hepatocellular Carcinoma in a Japanese Population: A Nested Case-Control Study; https://cir.nii.ac.jp/crid/1361981471028625024; Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy; https://cir.nii.ac.jp/crid/1362262946285996288; THE CLINICAL AND PATHOLOGICAL COURSE OF HEPATITIS B LIVER DISEASE IN RENAL TRANSPLANT RECIPIENTS; https://cir.nii.ac.jp/crid/1362544420087915264; Hepatitis viruses under immunosuppressive agents; https://cir.nii.ac.jp/crid/1362544421171752576; Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy; https://cir.nii.ac.jp/crid/1362825893477460736; Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B; https://cir.nii.ac.jp/crid/1362825894034183168; Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis; https://cir.nii.ac.jp/crid/1362825894374220928; Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate; https://cir.nii.ac.jp/crid/1362825894727258368; Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy; https://cir.nii.ac.jp/crid/1363107369707727232; Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection; https://cir.nii.ac.jp/crid/1363107370107354880; Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy; https://cir.nii.ac.jp/crid/1363388843277841280; Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan; https://cir.nii.ac.jp/crid/1363388843634951808; Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP; https://cir.nii.ac.jp/crid/1363388844884561536; Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan; https://cir.nii.ac.jp/crid/1363670319726192640; Entecavir as a first‐line treatment for HBV reactivation following polychemotherapy for lymphoma; https://cir.nii.ac.jp/crid/1363670319785928320; Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin’s lymphoma; https://cir.nii.ac.jp/crid/1363670320290960128; Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen; https://cir.nii.ac.jp/crid/1363951793209543424; Glucocorticoids in T Cell Development and Function; https://cir.nii.ac.jp/crid/1363951793538204032; Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy; https://cir.nii.ac.jp/crid/1363951794863329664; Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation; https://cir.nii.ac.jp/crid/1364233269508114944; Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy; https://cir.nii.ac.jp/crid/1364233269927331840; Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy; https://cir.nii.ac.jp/crid/1364233270311021312; Time Course of Histological Changes in Patients With A Sustained Biochemical and Virological Response to Corticosteroid Withdrawal Therapy for Chronic Hepatitis B; https://cir.nii.ac.jp/crid/1364233270487719936; 免疫抑制・化学療法により発症するＢ型肝炎対策：厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告; https://cir.nii.ac.jp/crid/1390001204795610880; Short-term prednisolone for inducing seroconversion from hepatitis B e antigen to antibody along with clinical improvement in patients with chronic active hapatitis type B.; https://cir.nii.ac.jp/crid/1390282679845565824
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: 雑誌記事索引データベース; https://ndlsearch.ndl.go.jp; Crossref; https://www.crossref.org; 科学研究費助成事業データベース; https://kaken.nii.ac.jp/ja
• 書誌ID（NDLBibID）: 11553500; http://id.ndl.go.jp/bib/11553500